Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Betamethasone

FDA-approved product (tablet, oral), marketed as Celestone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Betamethasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Eye inflammation
  • Hemorrhoid
  • Nasal congestion

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Corticosteroids acting locally; Corticosteroids; Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Betamethasone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Betamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea

    NCT02680717 · start 2016-03

    Registered record
    Registry ID
    NCT02680717
    Conditions
    Scleroderma
    Interventions
    Clobetasol; Calcipotriene; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2016-03
    Completion
    2017-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScleroderma
    InterventionClobetasol; Calcipotriene; Tacrolimus
    PhasePhase 1
    Registry statusWithdrawn

  • Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

    NCT02749799 · start 2016-02

    Registered record
    Registry ID
    NCT02749799
    Conditions
    Plaque Psoriasis
    Interventions
    DFD-01 (betamethasone dipropionate) Spray, 0.05%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-08
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDFD-01 (betamethasone dipropionate) Spray, 0.05%
    PhasePhase 4
    Registry statusCompleted

  • Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus

    NCT03525522 · start 2016-01-28

    Registered record
    Registry ID
    NCT03525522
    Conditions
    Lichen Sclerosus; Lichen Sclerosus Et Atrophicus
    Interventions
    Nd:YAG Laser; Topical corticosteroid Diprosone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-01-28
    Completion
    2018-05-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Sclerosus; Lichen Sclerosus Et Atrophicus
    InterventionNd:YAG Laser; Topical corticosteroid Diprosone
    PhaseNot applicable
    Registry statusUnknown

  • Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy

    NCT02652884 · start 2016-01

    Registered record
    Registry ID
    NCT02652884
    Conditions
    Transient Hypoparathyroidism
    Interventions
    phosphate and betamethasone acetate, 2 mL.; saline 0.9% NaCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2017-12
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransient Hypoparathyroidism
    Interventionphosphate and betamethasone acetate, 2 mL.; saline 0.9% NaCl
    PhasePhase 4
    Registry statusUnknown

  • Acute Unilateral Vestibulopathy and Corticosteroid Treatment

    NCT02912182 · start 2015-12

    Registered record
    Registry ID
    NCT02912182
    Conditions
    Vestibular Diseases; Vestibular Neuronitis
    Interventions
    Betamethasone; Placebo; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2021-03-01
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVestibular Diseases; Vestibular Neuronitis
    InterventionBetamethasone; Placebo; Prednisolone
    PhasePhase 4
    Registry statusTerminated

  • Ultrasound-guided Injection for DeQuervain's

    NCT02038634 · start 2014-08-05

    Registered record
    Registry ID
    NCT02038634
    Conditions
    DeQuervain's Tenosynovitis
    Interventions
    Betamethasone; Ultrasound
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-08-05
    Completion
    2021-03-15
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeQuervain's Tenosynovitis
    InterventionBetamethasone; Ultrasound
    PhasePhase 4
    Registry statusTerminated

  • Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment

    NCT01720485 · start 2013-10

    Registered record
    Registry ID
    NCT01720485
    Conditions
    Allergic Rhinitis
    Interventions
    Desloratadine + Prednisolone; Dexchlorpheniramine + Betamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2013-10
    Completion
    2014-03
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionDesloratadine + Prednisolone; Dexchlorpheniramine + Betamethasone
    PhasePhase 3
    Registry statusUnknown

  • Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients

    NCT01875107 · start 2013-08

    Registered record
    Registry ID
    NCT01875107
    Conditions
    Hyperglycemia in Pregnant Diabetic Patients
    Interventions
    insulin pre-treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2013-08
    Completion
    2014-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperglycemia in Pregnant Diabetic Patients
    Interventioninsulin pre-treatment
    PhasePhase 4
    Registry statusWithdrawn

  • The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome

    NCT02112513 · start 2012-11

    Registered record
    Registry ID
    NCT02112513
    Conditions
    Neonatal Respiratory Distress Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2017-06-30
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Respiratory Distress Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • SHP-141C in Plaque Type Psoriasis

    NCT01646567 · start 2012-09

    Registered record
    Registry ID
    NCT01646567
    Conditions
    Plaque Type Psoriasis
    Interventions
    SHP-141C; Placebo to SHP-141C; Betamethasone Valerate; Calcipotriol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-09
    Completion
    2012-11
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Type Psoriasis
    InterventionSHP-141C; Placebo to SHP-141C; Betamethasone Valerate; Calcipotriol
    PhasePhase 1
    Registry statusCompleted

  • Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous

    NCT01429701 · start 2012-05

    Registered record
    Registry ID
    NCT01429701
    Conditions
    Eczema
    Interventions
    polymyxin B sulphate + prednisolone + benzocaine + clioquinol; betamethasone + gentamicin + tolnaftato + cleoquinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2012-08
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema
    Interventionpolymyxin B sulphate + prednisolone + benzocaine + clioquinol; betamethasone + gentamicin + tolnaftato + cleoquinol
    PhasePhase 3
    Registry statusCompleted

  • Betamethasone and Severity of Hyaline Membrane Disease

    NCT01854840 · start 2012-01-12

    Registered record
    Registry ID
    NCT01854840
    Conditions
    Pregnant Women Receive Celesten
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-01-12
    Completion
    2018-12-31
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women Receive Celesten
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Platelet-rich Plasma Intra-articular Knee Injections for Knee Osteoarthritis

    NCT01381081 · start 2011-07

    Registered record
    Registry ID
    NCT01381081
    Conditions
    Knee Osteoarthritis
    Interventions
    platelet-rich plasma; Corticosteroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-01
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKnee Osteoarthritis
    Interventionplatelet-rich plasma; Corticosteroid
    PhasePhase 3
    Registry statusCompleted

  • Topical "Non-Aromatic Very Rich in Steranes" (NAVS) Naphthalan for the Treatment of Oral Mucosal Diseases

    NCT02920658 · start 2010-12

    Registered record
    Registry ID
    NCT02920658
    Conditions
    Oral Lichen Planus; Recurrent Aphthous Stomatitis
    Interventions
    NAVS Naphthalan; 0.05% Betamethasone dipropionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12
    Completion
    2013-11
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lichen Planus; Recurrent Aphthous Stomatitis
    InterventionNAVS Naphthalan; 0.05% Betamethasone dipropionate
    PhasePhase 2
    Registry statusCompleted

  • Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis

    NCT01768078 · start 2008-09

    Registered record
    Registry ID
    NCT01768078
    Conditions
    Post-operative Endophthalmitis
    Interventions
    Intravitreal injection of Betamethasone + antibiotics; Intravitreal injection of antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-09
    Completion
    2014-10
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-operative Endophthalmitis
    InterventionIntravitreal injection of Betamethasone + antibiotics; Intravitreal injection of antibiotics
    PhasePhase 3
    Registry statusCompleted